What's in CanSino Biologics Inc.'s pipeline?

CanSino Biologics Inc. has 21 drugs in our index: 3 marketed, 0 filed, 8 in Phase 3, 1 in Phase 2, 9 in Phase 1.

Which companies overlap with CanSino Biologics Inc.'s portfolio?

Top competitors by shared drug class: Pfizer, Merck Sharp & Dohme LLC, GlaxoSmithKline, Beijing Minhai Biotechnology Co., Ltd, National Institute of Allergy and Infectious Diseases (NIAID).

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/cansino-biologics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

CanSino Biologics Inc. — Portfolio Competitive Intelligence Brief

CanSino Biologics Inc. pipeline: 3 marketed, 0 filed, 8 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 8 Phase 3 1 Phase 2 9 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Placebo for Inhalation	Placebo for Inhalation	marketed
MCV4	MCV4	marketed	Meningococcal conjugate vaccine	Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules	Immunology / Infectious Disease
TT	TT	marketed	Viral vector vaccine	SARS-CoV-2 spike protein	Immunology / Infectious Disease
TTVA	TTVA	phase 3	vaccine		Infectious Disease
batch 2 of MCV4	batch 2 of MCV4	phase 3	Conjugate vaccine		Infectious Disease
DTcP	DTcP	phase 3	Vaccine		Immunology
MPSV4	MPSV4	phase 3	Meningococcal conjugate vaccine	Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules	Immunology / Infectious Disease
batch 3 of MCV4	batch 3 of MCV4	phase 3	Conjugate vaccine		Infectious Diseases
mRNA vaccine BNT162b2 (Pfizer)	mRNA vaccine BNT162b2 (Pfizer)	phase 3	mRNA vaccine	SARS-CoV-2 spike protein (S protein)	Immunology / Infectious Disease
PCV13i	PCV13i	phase 3	Conjugate vaccine		Infectious disease
MSPV4	MSPV4	phase 3	Meningococcal conjugate vaccine	Neisseria meningitidis serogroups B, C, W, Y polysaccharide antigens	Immunology / Infectious Disease

Therapeutic area mix

Immunology / Infectious Disease · 5
Infectious Disease · 2
Immunology · 1
Infectious Diseases · 1
Infectious disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 5 shared drug classes
Merck Sharp & Dohme LLC · 4 shared drug classes
GlaxoSmithKline · 4 shared drug classes
Beijing Minhai Biotechnology Co., Ltd · 4 shared drug classes
National Institute of Allergy and Infectious Diseases (NIAID) · 4 shared drug classes
London School of Hygiene and Tropical Medicine · 3 shared drug classes
International Vaccine Institute · 3 shared drug classes
Jiangsu Province Centers for Disease Control and Prevention · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for CanSino Biologics Inc.:

Cite this brief

Drug Landscape (2026). CanSino Biologics Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cansino-biologics-inc. Accessed 2026-05-16.